#MMSM
Where do ADCs fit in RRMM? Join Drs. Noopur Raje and Krina Patel on Jan 29 at 12 PM CST / 1 PM EST. They’ll compare ADCs with bispecifics and CAR T and talk through managing ocular AEs.

Free for SOHO members 👉 SOHO.click/Webinar1

#mmsm #MultipleMyeloma
November 21, 2026 at 2:03 PM
📣 THE PRELIMINARY PROGRAMME OF #ESHCART2027 IS AVAILABLE!
4th How I Manage CAR-T Therapies & Bispecific Antibodies for my Patients
Sept. 24-26, 2027|Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
To read it & for more info ➡ bit.ly/4ckiDZT
#ESHCONFERENCES #MMsm #Lmsm
November 13, 2026 at 11:59 AM
The Denver Nuggets apparently had an extra night in Mexico City after a maintenance issue on their charter flight to Houston. Turns out they flew out of NLU/MMSM (AIFA) (see
@theairshowpodcast.com
from Oct 22 w/ @crankyflier.com ): www.flightaware.com/live/flight/...
#avgeek
DL8924 (DAL8924) Delta Air Lines Flight Tracking and History 08-Nov-2026 (NLU / MMSM-KHOU) - FlightAware
Flight status, tracking, and historical data for Delta Air Lines 8924 (DL8924/DAL8924) 08-Nov-2026 (NLU / MMSM-KHOU) including scheduled, estimated, and actual departure and arrival times.
www.flightaware.com
November 9, 2026 at 3:20 AM
🎥 On this episode of #OncLiveOnAir, Noa Biran, MD, breaks down key multiple myeloma updates. #mmsm #hematology

Watch the video podcast on our site, or listen on your favorite podcast platforms! www.onclive.com/view/unpacki...
Unpacking Key Multiple Myeloma Data From ASCO 2026: With Noa Biran, MD (VIDEO) | OncLive
Noa Biran, MD, breaks down key multiple myeloma data shared at the 2026 ASCO Annual Meeting.
www.onclive.com
November 9, 2026 at 6:52 PM
🩸An @fda.gov approval in CLL and breakthrough therapy destinations? October was a busy month in the hematologic malignancy space!

Get caught up here 📰: www.onclive.com/view/fda-fla...

#oncology #lymsm #leusm #mmsm #mpnsm
FDA Flashback: Hematologic Cancer Decisions and News From October 2026 | OncLive
Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.
www.onclive.com
November 9, 2026 at 6:08 PM
Treatment with the allogeneic g-NK cell therapy IDP-023 plus isatuximab yielded responses in heavily pretreated R/R multiple myeloma, including in those who received prior T-cell–redirecting therapy #SITC26 #mmsm #oncology

Read more from a phase 1 study: www.onclive.com/view/idp-023...
November 7, 2026 at 1:47 AM
In patients with newly diagnosed #MMsm not undergoing upfront autologous HSCT, indefinite maintenance therapy with lenalidomide was not found to produce significantly longer OS when compared with fixed-duration therapy, at 68.6% vs. 69%, respectively: https://ow.ly/fNjQ5104i3I
November 6, 2026 at 2:30 PM
New Crush City Territory episode

- First impressions of Randy Flores
- Jim Crane's comments
- More

YouTube: www.youtube.com/watch?v=mmsM...

Apple: podcasts.apple.com/us/podcast/c...

Spotify: open.spotify.com/episode/6z4X...
The Flores Files: First Impressions of the Astros’ New GM | Crush City Territory
YouTube video by Crush City Territory: A Houston Astros Show
www.youtube.com
November 3, 2026 at 4:53 PM
Ongoing research and evolving prophylactic measures are helping integrate bispecific antibodies further into community practice for the management of relapsed/refractory multiple myeloma #mmsm #oncology

Read more: www.onclive.com/view/outpati...
Outpatient Models and Prophylactic Measures Help Bring Bispecifics Into Community Practice for R/R Myeloma | OncLive
Faculty at an OncLive Scientific Interchange and Workshop discussed operationalizing outpatient bispecific antibody therapy for relapsed/refractory multiple myeloma.
www.onclive.com
November 3, 2026 at 4:00 PM
CMS has expanded Medicare coverage for autologous stem cell transplants for patients with multiple myeloma!

ASH applauds this decision, which follows collaborative advocacy efforts to improve access to care.

Read more: https://ow.ly/cJvr5102r9l

#Hematology #MMsm
October 30, 2026 at 5:54 PM
Who is this new CELMoD for? Learn more about Zenbexus, the first CELMoD approved for multiple myeloma treatment.

#AsktheIMF #mmsm
October 26, 2026 at 8:08 PM
Combining the bispecific antibody teclistamab with daratumumab and lenalidomide resulted in deep responses among patients with newly diagnosed #MMsm who were eligible for stem cell transplant, with an MRD-negative CR of 91.8% and a 100% ORR at six months: https://ow.ly/wcXS5100I5b
October 27, 2026 at 3:00 PM
Topline data from the phase 3 MagnetisMM-32 trial showed elranatamab improved PFS vs SOC in R/R multiple myeloma treated with at least 1 prior line of therapy that included an anti-CD38 monoclonal antibody and lenalidomide #mmsm #oncology

Read more: www.onclive.com/view/elranat...
October 27, 2026 at 2:26 PM
Just in: Teclistamab monotherapy is now approved in the EU for relapsed/refractory multiple myeloma following at least 1 prior line of therapy #mmsm #oncology

Read more: www.onclive.com/view/teclist...
October 23, 2026 at 3:45 PM
Following the June 2026 approval of subcutaneous isatuximab by Japan's Ministry of Health, Labour and Welfare, the regulatory agency has also approved the CirCLIQ injector for on-body administration of the anti-CD38 antibody in multiple myeloma #mmsm #oncology www.onclive.com/view/japan-a...
Japan Approves On-Body Injector for Subcutaneous Isatuximab in Multiple Myeloma | OncLive
The CirCLIQ Injector approval for subcutaneous isatuximab in multiple myeloma is the first anticancer treatment delivered via an on-body injector in Japan.
www.onclive.com
October 19, 2026 at 4:14 PM
📣 PRESENTING THE MAIN TOPICS OF #ESHCART2027
4th How I Manage CAR-T Therapies & Bispecific Antibodies for my Patients
Sept. 24-26, 2027|Stockholm, Sweden
Chairs: Michael Hudecek, Caron Jacobson, Marie José Kersten
For more information ➡ bit.ly/4ckiDZT
#ESHCONFERENCES #HAEMATOLOGY #MMsm #Lmsm
October 14, 2026 at 8:46 AM
Wheels down for Sergio Perez at MMSM. 4h 45m on XA-ASP, the Bombardier Challenger 604. FL381 cruise · ~1,188 gal.
#celebplanes #celebjettracking #privatejet #avgeek #sergioperez #bombardierchallenger604
celebplanes.com/flight/26312
October 13, 2026 at 9:08 PM
Is multiple myeloma hereditary, environmental, or both? IMF Nurse Leadership Board member Beth Faiman explains in this short clip.

#AsktheIMF #mmsm
October 13, 2026 at 2:01 PM
tá joia, chuchu, brigadinho assim mmsm ^_^
October 12, 2026 at 7:09 PM
CAR T or bispecifics at early relapse? Omar Castaneda Puglianini, MD, of @moffittnews.bsky.social, breaks down considerations for treatment selection/sequencing as T-cell–redirecting therapies continue to move earlier in the myeloma treatment paradigm #mmsm #oncology www.onclive.com/view/earlier...
Earlier CAR T-Cell Therapy Use Highlights Sequencing and Access Considerations in Myeloma | OncLive
Omar Castaneda Puglianini, MD, discusses earlier CAR T-cell therapy use, sequencing with bispecific antibodies, and access barriers in multiple myeloma.
www.onclive.com
October 13, 2026 at 1:07 PM
📣 #ESHLYMPHOMA2026 PROGRAMME HIGHLIGHT:
ROUNDTABLE 1 “TOX and PRO”
5th How to Diagnose and Treat Lymphoma
October 29-31, 2026 / Prague, Czech Republic
Chairs: Christian Buske, Michael Crump, Gilles Salles, Catherine Thieblemont
More info ➡ bit.ly/42eJ3s6
#ESHCONFERENCES #Haematology #MMsm #Lmsm
October 13, 2026 at 7:40 AM
Last week’s #OncFive:
✅ Atezolizumab approved for CRC #crcsm #oncology
🎗️ Tucatinib approved for breast cancer #bcsm
🩸 IberDd hits PFS in myeloma #mmsm #hematology
🔵 Fast track for VIR-5500 in mCRPC #pcsm
🩸 Epcoritamab+R-CHOP hits PFS in DLBCL #lymsm

www.onclive.com/view/the-onc...
The OncFive: Top Oncology Articles for the Week of 10/4/2026 | OncLive
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
www.onclive.com
October 11, 2026 at 12:27 PM
How are experts navigating subcutaneous therapy administrations in multiple myeloma? Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, break down newer patient-centric approaches #mmsm #oncology

Listen now: www.onclive.com/view/navigat...
Navigating Patient-Centric Treatment Administration Strategies in Myeloma | OncLive
Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discuss how on-body administration methods are affecting myeloma management.
www.onclive.com
October 9, 2026 at 7:27 PM